Clinical studies testing the effects of autophagy modulators on cancer therapies
| Cancer Type | Status | Therapeutic Regimen | Autophagy Modulation | Identifier |
|---|---|---|---|---|
| Renal cell cancer | Phase I | HCQ | Inhibition | NCT01144169 |
| Phase II | Everolimus | Activation | NCT00830895 | |
| Phase I/II | Temsirolimus + gemcitabine and cisplatin | NCT01090466 | ||
| Prostate cancer | Phase II | HCQ | Inhibition | NCT00726596 |
| Phase II | HCQ + docetaxel | NCT00786682 | ||
| Phase II | Everolimus + pasireotide | Activation | NCT01313559 | |
| Phase I/II | Everolimus + docetaxel and bevacizumab | NCT00574769 | ||
| Breast cancer | Phase II | HCQ | Inhibition | NCT01292408 |
| Phase I/II | HCQ + ixabepilone | NCT00765765 | ||
| Phase I/II | CQ + tamoxifen | NCT01023477 | ||
| Phase II | Rapamycin + trastuzumab | Activation | NCT00411788 | |
| Phase I/II | Temsirolimus + neratinib | NCT01111825 | ||
| Non–small cell lung cancer | Phase II | HCQ + erlotinib | Inhibition | NCT00977470 |
| Phase I/II | HCQ + gefitinib | NCT00809237 | ||
| Phase I/II | HCQ + bevacizumab, carboplatin, and paclitaxel | NCT00933803 | ||
| Phase II | Temsirolimus | Activation | NCT00079235 | |
| Phase I/II | Sirolimus + pemetrexed | NCT00923273 | ||
| Small cell lung cancer | Phase I/II | CQ + radiation | Inhibition | NCT00969306 |
| Phase II | Everolimus | Activation | NCT00374140 | |
| Phase I/II | Everolimus + paclitaxel | NCT01079481 | ||
| Pancreatic cancer | Phase II | HCQ | Inhibition | NCT01273805 |
| Phase I/II | HCQ + gemcitabine | NCT01128296 | ||
| Phase I | HCQ + sunitinib | NCT00813423 | ||
| Phase II | Everolimus | Activation | NCT01648465 | |
| Phase I | Sirolimus + vismodegib | NCT01537107 | ||
| Glioblastoma | Phase I/II | HCQ + temozolomide + radiation | Inhibition | NCT00486603 |
| Phase III | CQ | NCT00224978 | ||
| Phase I/II | Temsirolimus + sorafenib | Activation | NCT00329719 | |
| Phase I/II | Everolimus + temozolomide and radiation | NCT01062399 | ||
| Colorectal cancer | Phase I/II | HCQ + FOLFOX + bevacizumab | Inhibition | NCT01206530 |
| Phase I/II | HCQ + capecitabine, oxaliplatin, and bevacizumab | NCT01006369 | ||
| Phase I/II | Everolimus + irinotecan and cetuximab | Activation | NCT00522665 | |
| Phase I | Everolimus + OSI-906 | NCT01154335 | ||
| Chronic myeloid leukemia | Phase II | HCQ + imatinib | Inhibition | NCT01227135 |
| Phase I/II | Everolimus | Activation | NCT01188889 | |
| Chronic lymphocytic leukemia | Phase II | HCQ | Inhibition | NCT00771056 |
| Phase I/II | Everolimus + alemtuzumab | Activation | NCT00935792 | |
| Advanced solid tumor | Phase I | HCQ + sunitinib | Inhibition | NCT00813423 |
| Phase I | HCQ + temozolomide | NCT00714181 | ||
| Phase I | HCQ + temsirolimus | NCT00909831 | ||
| Phase I | HCQ + vorinostat | NC01023737 | ||
| Phase I | HCQ + sirolimus or vorinostat | NCT01266057 | ||
| Phase I | Everolimus + capecitabine, oxaliplatin, and bevacizumab | Activation | NCT00849550 | |
| Phase I/II | Temsirolimus | NCT01020305 | ||
| Phase II | Everolimus | NCT00657982 | ||
| Phase I | Temsirolimus + vinorelbine | NCT01155258 | ||
| Multiple myeloma | Phase I/II | HCQ + bortezomib | Inhibition | NCT00568880 |
| Phase I | HCQ + cyclophosphamide, dexamethasone, and rapamycin | NCT01689987 | ||
| Phase I | Temsirolimus + dexamethasone | Activation | NCT00693433 | |
| Phase I | Temsirolimus + lenalidomide | NCT00398515 | ||
| Phase I/II | Everolimus + panobinostat | NCT00918333 | ||
| Phase I/II | Everolimus + sorafenib | NCT00474929 | ||
| Ovarian cancer | Phase II | Temsirolimus | Activation | NCT01460979 |
| Phase I | Temsirolimus + pegylated liposomal doxorubicin | NCT00982631 | ||
| Phase II | Temsirolimus + carboplatin and paclitaxel | NCT01196429 | ||
| Phase II | Temsirolimus + bevacizumab | NCT01010126 | ||
| Phase II | Everolimus + bevacizumab | NCT01031381 | ||
| Phase I | Everolimus + carboplatin and pegylated liposomal doxorubicin hydrochloride | NCT01281514 | ||
| Melanoma | Phase I | HCQ | Inhibition | NCT00962845 |
| Phase II | Temsirolimus + selumetinib | Activation | NCT01166126 | |
| Phase II | Everolimus + paclitaxel and carboplatin | NCT01014351 |
FOLFOX (regimen), oxaliplatin, 5-fluorouracil, and folinic acid; OSI-906, 3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol.